Oppenheimer Forecasts Strong Price Appreciation for Sagimet Biosciences (NASDAQ:SGMT) Stock

Key Points

• Oppenheimer raised Sagimet Biosciences’ price target to $38 from $33 and maintained an “outperform” rating, implying substantial upside from the stock’s recent close. Analysts overall give SGMT a “Moderate Buy” consensus with a $26.52 average target.
• Sagimet reported encouraging 52-week Phase 3 extension results for denifanstat in moderate-to-severe acne, including a 56.7% Investigator’s Global Assessment success rate and significant lesion reductions. The company plans to begin screening for its roughly 800-patient U.S. AURORA Phase 3 trial in October.
• The company raised $115 million through a stock and pre-funded warrant offering to fund its Phase 3 program, strengthening its balance sheet but creating potential shareholder dilution.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) had its price objective upped by equities research analysts at Oppenheimer from $33.00 to $38.00 in a report issued on Thursday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Oppenheimer's price objective would indicate a potential upside of 284.62% from the company's previous close.

Several other equities analysts also recently weighed in on the company. Wall Street Zen downgraded Sagimet Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Citigroup reissued a "market outperform" rating on shares of Sagimet Biosciences in a research report on Thursday. Barclays upgraded Sagimet Biosciences from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $8.00 to $18.00 in a research note on Wednesday, September 9th. The Goldman Sachs Group initiated coverage on Sagimet Biosciences in a report on Thursday, September 24th. They set a "sell" rating and a $7.00 price target on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Sagimet Biosciences in a research report on Friday, July 17th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $26.52.

Sagimet Biosciences Price Performance

NASDAQ:SGMT opened at $9.88 on Thursday. The firm's 50-day moving average price is $9.74 and its 200-day moving average price is $7.72. The company has a market capitalization of $614.14 million, a PE ratio of -7.72 and a beta of 3.45. Sagimet Biosciences has a 1-year low of $4.50 and a 1-year high of $11.45.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Equities analysts anticipate that Sagimet Biosciences will post -1.19 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO David Happel sold 64,051 shares of the business's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $7.76, for a total transaction of $497,035.76. Following the completion of the sale, the chief executive officer owned 741,570 shares of the company's stock, valued at $5,754,583.20. The trade was a 7.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total value of $201,049.70. Following the completion of the sale, the director owned 62,161 shares of the company's stock, valued at $618,501.95. This trade represents a 24.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 113,646 shares of company stock worth $920,491. Company insiders own 11.50% of the company's stock.

Hedge Funds Weigh In On Sagimet Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its holdings in Sagimet Biosciences by 82.6% during the first quarter. Renaissance Technologies LLC now owns 625,469 shares of the company's stock valued at $3,268,000 after purchasing an additional 282,969 shares during the period. Seven Fleet Capital Management LP purchased a new position in shares of Sagimet Biosciences during the 2nd quarter valued at about $3,119,000. Bank of New York Mellon Corp bought a new position in shares of Sagimet Biosciences during the 2nd quarter valued at approximately $1,551,000. Dimensional Fund Advisors LP grew its stake in shares of Sagimet Biosciences by 99.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company's stock valued at $1,415,000 after acquiring an additional 135,178 shares during the period. Finally, AWM Investment Company Inc. purchased a new stake in Sagimet Biosciences in the 2nd quarter worth approximately $618,000. 87.86% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: Denifanstat delivered encouraging 52-week Phase 3 open-label extension results in moderate-to-severe acne. The treatment produced a 56.7% Investigator’s Global Assessment success rate, reduced total lesions by 71.8% and inflammatory lesions by 76.9%, and was generally well tolerated, with no permanent discontinuations attributed to adverse events. Sagimet Announces Positive Full 52-Week Results
• Positive Sentiment: Sagimet plans to begin screening patients for its approximately 800-patient U.S. AURORA Phase 3 acne trial in October. The data support the company’s strategy to advance denifanstat, a once-daily oral FASN inhibitor, toward the U.S. market. Sagimet Phase 3 Data and U.S. Phase 3 Plans
• Positive Sentiment: Oppenheimer raised its price target for SGMT to $38, signaling substantial potential upside if denifanstat’s U.S. development program succeeds. Oppenheimer Raises Sagimet Price Target
• Neutral Sentiment: The positive efficacy results came from a Chinese trial conducted by license partner Ascletis. Investors will likely focus on whether the findings translate to the U.S. AURORA trial and ultimately support regulatory approval.
• Negative Sentiment: Sagimet priced a $115 million underwritten offering of 8.75 million Series A shares at $10 per share, with pre-funded warrants representing another 2.75 million shares. The financing strengthens the balance sheet and funds the Phase 3 program, but the potentially substantial increase in shares outstanding is pressuring the stock through dilution concerns. Sagimet Prices $115 Million Offering

Sagimet Biosciences Company Profile

Sagimet Biosciences, Inc is a clinical-stage biopharmaceutical company developing therapies for diseases associated with abnormal lipid metabolism. The company's primary focus is fatty acid synthase (FASN), an enzyme involved in the production of fatty acids that can contribute to disease progression in certain metabolic and inflammatory conditions.

Sagimet's lead product candidate is denifanstat, formerly known as TVB-2640. Denifanstat is an orally administered, selective FASN inhibitor being evaluated primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can lead to fibrosis, cirrhosis and other serious complications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.